Institutional members access full text with Ovid®

Comment on: Rifaximin in the Treatment of Irritable Bowel Syndrome. Is There a High Risk for Development of Antimicrobial Resistance?

Calanni, Fiorella DSc*; Renzulli, Cecilia PhD*; Fogli, Maria V. PhD; Barbanti, Miriam DSc*

Journal of Clinical Gastroenterology: October 2013 - Volume 47 - Issue 9 - p 814
doi: 10.1097/MCG.0b013e3182951b6c
Letters to the Editor